Knights of Columbus Asset Advisors LLC Holds Stake in Amgen Inc. (AMGN)
Knights of Columbus Asset Advisors LLC continued to hold its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,400 shares of the medical research company’s stock at the end of the second quarter. Knights of Columbus Asset Advisors LLC’s holdings in Amgen were worth $413,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of the business. Canada Pension Plan Investment Board lifted its holdings in shares of Amgen by 65.7% in the second quarter. Canada Pension Plan Investment Board now owns 1,706,261 shares of the medical research company’s stock worth $293,869,000 after buying an additional 676,300 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Amgen in the first quarter worth $110,402,000. Swiss National Bank lifted its holdings in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares in the last quarter. Bank of Nova Scotia lifted its holdings in shares of Amgen by 414.4% in the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after buying an additional 484,868 shares in the last quarter. Finally, First Eagle Investment Management LLC purchased a new position in shares of Amgen in the second quarter worth $71,081,000. 78.20% of the stock is currently owned by institutional investors and hedge funds.
Shares of Amgen Inc. (AMGN) opened at $171.50 on Tuesday. Amgen Inc. has a one year low of $138.83 and a one year high of $191.10. The firm has a market cap of $125,110.70, a PE ratio of 13.70, a P/E/G ratio of 2.50 and a beta of 1.37. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period in the prior year, the firm earned $3.02 earnings per share. The firm’s revenue for the quarter was down .7% compared to the same quarter last year. analysts anticipate that Amgen Inc. will post 12.66 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be paid a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is presently 41.63%.
Amgen announced that its board has approved a stock buyback plan on Wednesday, October 25th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.
Several research firms have recently commented on AMGN. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price on the stock. in a report on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $203.00 target price (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Royal Bank Of Canada began coverage on shares of Amgen in a report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 target price on the stock. Credit Suisse Group reissued a “neutral” rating and issued a $186.00 target price (up previously from $177.00) on shares of Amgen in a report on Friday, September 29th. Finally, Cowen and Company reissued an “outperform” rating and issued a $209.00 target price on shares of Amgen in a report on Saturday, July 22nd. Thirteen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Amgen has a consensus rating of “Buy” and a consensus price target of $190.03.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.